MedTrace Logo

Clinical Comprehensive Evaluation of Neuroprotective Drugs for Acute Ischemic Stroke

NCT07260760 · Status: NOT_YET_RECRUITING · Type: OBSERVATIONAL · Enrollment: 600

Last updated 2026-01-15

No results posted yet for this study

Summary

This study conducted a comprehensive evaluation of commonly used neuroprotective agents in acute ischemic stroke, assessing their real-world value across six dimensions: safety, efficacy, cost-effectiveness, innovativeness, appropriateness, and accessibility. Employing a prospective observational design, it primarily investigates the association of edaravone and dexrazoxane with clinical outcomes in patients with mild-to-moderate stroke, with subgroup analyses performed according to Trial of Org 10172 in Acute Stroke Treatment （TOAST ）classification.

Conditions

  • Acute Ischemic Stroke

Sponsors & Collaborators

  • Qianfoshan Hospital

    lead OTHER

Principal Investigators

  • Xiaofang Niu · Heze Municipal Hospital

  • Leqing Zhang · Yanggu County People's Hospital

  • Lei Duan · Zibo Central Hospital

  • Kai Ren · Haiyang People's Hospital

  • Rongrong Zhang · Sishui County People's Hospital

  • Ping Yang · Jinan Fourth People's Hospital

  • Ning Liu · Shandong Hospital of Integrated Traditional Chinese and Western Medicine

  • Pengcheng Du · Qilu Hospital of Shandong University, Dezhou Branch

  • Hui Liu · Jinan Municipal People's Hospital

  • Xi Rong · Weifang Yidu Central Hospital

  • Deyin Zhai · Linyi Traditional Chinese Medicine Hospital

  • Zhiqiang Zhang · Anqiu People's Hospital

  • Jiyong Wu · Shandong Provincial Second People's Hospital

  • Meixia Wang · Jining Medical University Affiliated Hospital

  • Ping Wang · Liaocheng People's Hospital

  • Jiyao Li · Liaocheng Municipal People's Hospital

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2026-01-20
Primary Completion
2028-12-31
Completion
2028-12-31

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT07260760 on ClinicalTrials.gov